Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3-mediated N6-methyladenosine modification of ICAM2 mRNA in fibroblast-like synoviocytes.
Jian ChenXian LinJuan HeDandan LiuLianhua HeMiaomiao ZhangHuijie LuanYiping HuCheng TaoQingwen WangPublished in: Clinical and translational medicine (2022)
We provided strong evidence that ATT has therapeutic potential for RA management by suppressing proliferation, migration and invasion, in addition to inducing apoptosis of RA-FLSs through modulating METTL3/ICAM2/PI3K/AKT/p300 feedback loop, supplying the fundamental basis for the clinical application of ATT in RA therapy. Moreover, METTL3, ICAM2 and p300 might serve as biomarkers for the therapy response of RA patients.
Keyphrases
- rheumatoid arthritis
- signaling pathway
- pi k akt
- disease activity
- cell cycle arrest
- ankylosing spondylitis
- end stage renal disease
- interstitial lung disease
- newly diagnosed
- cell proliferation
- chronic kidney disease
- ejection fraction
- oxidative stress
- cell death
- endoplasmic reticulum stress
- prognostic factors
- stem cells
- transcription factor
- patient reported
- idiopathic pulmonary fibrosis